BMI requirements for GLP-1 weight loss medications come down to two FDA thresholds: a BMI of 30 or higher, or a BMi of 27 or higher paired with a weight-related condition like high blood pressure, type 2 diabetes, or sleep apnea. Everything else that patients worry about, insurance approval, dosing, which brand, sits downstream of that one number.
TL;DR
- Wegovy and Zepbound require BMI 30+, or BMI 27+ with a weight-related condition such as hypertension or type 2 diabetes.
- Ozempic and Mounjaro carry a type 2 diabetes indication, not an obesity indication, so their eligibility logic runs differently.
- GoodLife Health's Cardiometabolic Optimization Membership pairs the BMI requirements for GLP-1 with quarterly Biomarker Audits to confirm eligibility beyond the scale.
- Meeting the BMI cutoff does not guarantee insurance coverage; documented comorbidities are what carries a prior authorization.
- Wegovy and Zepbound require BMI 30+, or BMI 27+ with a qualifying comorbidity like hypertension or type 2 diabetes.
- Ozempic and Mounjaro are FDA-approved for type 2 diabetes, not obesity, so weight-loss use is off-label.
- Documented comorbidities, not the BMI number alone, are what carries a prior authorization with insurers.
- GoodLife Health's Cardiometabolic Optimization Membership pairs BMI eligibility with quarterly Biomarker Audits covering ApoB, Lp(a), hs-CRP, HbA1c, and thyroid/hormone panels.
- Compounded semaglutide or tirzepatide bypasses the BMI-and-labs framework entirely and isn't FDA-approved.
- In clinical trials, the highest tirzepatide dose produced roughly 22.5% average weight loss at 72 weeks versus roughly 15% for semaglutide at 68 weeks.
Why this matters
BMI is the first filter, not the whole clinical picture. The FDA label for Wegovy and Zepbound uses body mass index because it's a fast, reproducible way to define obesity at a population level, but a clinician still needs the rest of the picture, blood pressure, HbA1c, lipids, thyroid function, before writing a prescription that actually fits your risk profile. That's the model GoodLife Health built its Cardiometabolic Optimization Membership around: BMI opens the door, and quarterly labs decide what happens next.
BMI is the first filter, not the whole clinical picture.
Meeting a BMI cutoff doesn't guarantee insurance coverage, and it doesn't guarantee a medication is the right fit for your labs. The number on the FDA label decides which branded GLP-1 is even on the table in 2026. Everything downstream of that, dose titration, medication choice, side-effect management, depends on documentation that goes well beyond a single BMI calculation.
What the BMI requirements for GLP-1 actually say
For adults with BMI 27 and above who are weighing GLP-1 therapy, the medication landscape splits into two indications, and mixing them up is the single most common source of confusion. Wegovy (semaglutide 2.4mg) and Zepbound (tirzepatide) both carry an FDA obesity indication: BMI 30 or higher on its own, or BMI 27 or higher with at least one qualifying weight-related condition. Ozempic and Mounjaro carry a type 2 diabetes indication instead, so their approval doesn't hinge on a BMI number the same way; clinicians who prescribe them for weight loss are doing so off-label, and most still use the 27/30 framework as clinical judgment even though it isn't the FDA-mandated cutoff for those two drugs.
Zepbound and Mounjaro are the same molecule, tirzepatide, dosed and marketed for two different indications. Cash-pay patients pursuing weight loss are routed to Zepbound; Mounjaro is built for insurance-covered type 2 diabetes management. Oral options exist too: Wegovy Tablets and Foundayo (orforglipron) carry a similar weight-management framing, so the BMI conversation applies to them as well, not just the injectables.
The qualifying comorbidities that unlock the BMI 27+ tier are specific, not vague "you feel unwell" complaints. A clinician is generally looking for:
- Hypertension, typically blood pressure readings at or above 130/80 on repeated checks
- Type 2 diabetes or prediabetes, usually confirmed by an HbA1c of 5.7% or higher
- Dyslipidemia, meaning elevated LDL or triglycerides on a lipid panel
- Obstructive sleep apnea, confirmed by a sleep study rather than self-reported snoring
- Established cardiovascular disease
A family history of diabetes or heart disease, by itself, doesn't count. It has to show up in your own labs or diagnosis history.
Calculate your BMI correctly before you assume you don't qualify
Most people miscalculate their own BMI before they ever talk to a clinician, usually by using an old height or a scale reading taken at the wrong time of day.
- Use your actual height without shoes, measured within the last year
- Weigh yourself in the morning, before food or water, for consistency
- Recalculate after any 5+ pound swing rather than relying on a number from months ago
- Round to the nearest tenth rather than the nearest whole number, since 26.6 and 27.1 land in different eligibility tiers
- Don't average multiple different scales; pick one and stay consistent
Check whether you carry a qualifying comorbidity
If your BMI sits between 27 and 29.9, the comorbidity is what actually gets you into the medication, not the BMI number alone.
- Pull your last two blood pressure readings from any recent visit
- Ask for your most recent HbA1c or fasting glucose if you haven't had one in the last 12 months
- Request your lipid panel numbers, specifically LDL and triglycerides
- Confirm whether a prior sleep study documented obstructive sleep apnea
- Note any existing cardiovascular diagnosis, even a resolved one, in your chart
Confirm which GLP-1 medication matches your BMI tier and indication
Once you know your BMI tier and comorbidity status, the medication choice narrows fast.
- BMI 30+, or 27+ with a comorbidity, and no diabetes diagnosis: Wegovy or Zepbound are the on-label options
- BMI 30+ and type 2 diabetes: Ozempic or Mounjaro fit the diabetes indication, with weight loss as a secondary benefit
- Preference for a pill over an injection: Wegovy Tablets or Foundayo, evaluated under the same weight-management framing
- Compounded semaglutide or tirzepatide from a med spa: skip this route. It isn't FDA-approved, dosing isn't standardized, and it sidesteps the entire BMI-and-labs framework that keeps treatment safe
Get baseline biomarkers drawn before you start treatment
A BMI number tells a clinician almost nothing about your thyroid, your inflammation levels, or how your body is actually handling glucose. This is where the medical weight loss clinic for adults with obesity model differs from a five-minute intake form: GoodLife Health's Biomarker Audit runs every 90 days and covers ApoB, Lp(a), hs-CRP, HbA1c, and full hormone and thyroid panels, so dosing decisions are made against real data, not just a scale reading.
- ApoB and Lp(a) for cardiovascular risk that a standard lipid panel misses
- hs-CRP as a marker of systemic inflammation
- HbA1c to confirm or rule out a diabetes-related comorbidity
- Full thyroid panel, since untreated hypothyroidism can blunt GLP-1 response
- Hormone panel, because weight, thyroid, and hormones move as one interconnected system, not three separate problems
Full thyroid panel, since untreated hypothyroidism can blunt GLP-1 response.
Talk to a licensed clinician about eligibility, not just an intake form
A form can capture your BMI. It can't catch a contraindication.
- Bring your actual blood pressure readings, not a guess
- List every current medication, including anything that affects appetite or metabolism
- Disclose any personal or family history of medullary thyroid cancer or MEN 2, a hard contraindication for GLP-1s
- Mention any history of pancreatitis or gallbladder disease before starting
- Ask directly how your BMI tier and comorbidities were documented, since that documentation is what insurance reviews later
Plan for what happens when your BMI changes after treatment starts
GLP-1 therapy works. That means your BMI tier won't stay put, and the plan needs to account for that instead of treating the starting number as permanent.
- Track BMI as a trend line over months, not a single reading
- Re-check labs after meaningful weight loss, since thyroid and hormone doses can need adjusting as body composition shifts
- Discuss a maintenance dose before you drop below the original qualifying tier, not after
- Watch for signs of lean muscle loss alongside fat loss, which BMI alone can't distinguish
- Ask whether your clinician re-evaluates comorbidity status once blood pressure or HbA1c normalizes
Comparing your paths to GLP-1 treatment by BMI tier
Meeting the BMI requirement is step one. How you get the prescription, and whether anyone is tracking your labs afterward, is a separate decision.
Comparing your paths to GLP-1 treatment by BMI tier
Meeting the BMI requirement is step one
| Pathway | Best for | Key limitation | Verdict |
|---|---|---|---|
| GoodLife Health Cardiometabolic Optimization Membership | Adults who want BMI eligibility paired with quarterly Biomarker Audits and hormone/thyroid monitoring | Starts with a two-month commitment before month-to-month billing | Buy for BMI plus labs together |
| Insurance-based primary care | Patients whose plan already covers Wegovy or Zepbound with prior authorization | Prior authorization is commonly denied when comorbidity documentation is incomplete | Hold if coverage is confirmed |
| Direct-to-consumer telehealth (branded GLP-1) | Adults who mainly need a fast prescription | Quarterly lab tracking is often not built into the visit | Hold for speed only |
| Compounded semaglutide or tirzepatide through a med spa | Nobody GoodLife Health recommends | Not FDA-approved, dosing isn't standardized, and it bypasses the BMI-and-labs framework entirely | Skip |
Common mistakes adults make with GLP-1 BMI requirements
- Treating one BMI reading as fixed. Hydration, time of day, and even clothing can swing the number enough to cross the 27 or 30 line.
- Assuming the 27+ tier applies automatically. It requires a documented comorbidity, hypertension, prediabetes, dyslipidemia, sleep apnea, not just a feeling of being unwell.
- Confusing indications. Ozempic and Mounjaro's diabetes indication is not the same as Wegovy and Zepbound's weight-management indication, and mixing them up is a common reason prior authorizations get denied.
- Turning to compounded GLP-1s to dodge the paperwork. That trades an FDA-approved, pharmacy-dispensed dose for an unregulated one, and it's a route GoodLife Health does not offer under any circumstance.
- Stopping biomarker tracking once the prescription starts. Missing early signs of muscle loss or a thyroid dose that needs adjusting is one of the most avoidable errors in medical weight loss.
FAQ
What BMI do you need for Wegovy or Zepbound?
You need a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. This is the FDA-labeled threshold for both drugs' obesity indication.
Can you get GLP-1 medication with a BMI under 27?
Not under the FDA-approved obesity indication for Wegovy or Zepbound. A clinician may still discuss other medically supervised weight-loss options, but branded GLP-1 therapy for obesity specifically requires the 27+ or 30+ threshold.
Does Ozempic have a BMI requirement for weight loss?
Ozempic is FDA-approved for type 2 diabetes, not obesity, so it doesn't carry the same 27/30 BMI framework as Wegovy. When it's used for weight loss, that use is off-label and BMI becomes a clinical judgment factor rather than a labeled requirement.
What comorbidities count toward the BMI 27 threshold?
Hypertension, type 2 diabetes or prediabetes, dyslipidemia, obstructive sleep apnea, and established cardiovascular disease are the standard qualifying conditions. Each needs to be documented in your medical history or recent labs, not just self-reported.
Is BMI the only qualifying factor for GLP-1 therapy?
No. BMI decides which medication is on the table, but a clinician also reviews thyroid function, cardiovascular risk markers, and personal or family history of conditions like medullary thyroid cancer before prescribing.
How is BMI calculated for GLP-1 eligibility?
BMI is calculated from height and weight using the standard formula, weight in kilograms divided by height in meters squared. Clinicians typically want a current, accurately measured height and weight rather than a self-reported estimate from months earlier.
Can insurance deny GLP-1 coverage even if you meet the BMI requirement?
Yes. Meeting the BMI threshold is necessary but not sufficient; insurers commonly require documented proof of a qualifying comorbidity, and incomplete documentation is one of the most frequent reasons prior authorizations get denied.
**What happens if your BMI drops below the treat
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/